Delving into the Latest Updates on Pembrolizumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Lambrolizumab, Pembrolizumab (Genetical Recombination), Pembrolizumab (genetical recombination) (JAN)

+ [12]

Target

PD-1

Action

inhibitors

Mechanism

PD-1 inhibitors(Programmed cell death protein 1 inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesInfectious Diseases+ [12]

Active Indication

Fallopian Tube CarcinomaNon-Muscle Invasive Bladder NeoplasmsOvarian Epithelial Carcinoma+ [320]

Inactive Indication

Acral Lentiginous Malignant MelanomaAcute Myeloid LeukemiaAcute myeloid leukemia with mutated NPM1+ [127]

Originator Organization

Merck & Co., Inc.

Active Organization

Merck Sharp & Dohme LLC

MSD R&D (China) Co. Ltd.

Merck Sharp & Dohme Corp.

+ [15]

Inactive Organization

Merck Sharp & Dohme (Ireland) Ltd.

Turnstone Biologics Corp.

Eisai GmbH

+ [1]

License Organization

Nektar Therapeutics

NeoImmuneTech, Inc.

Canada Pension Plan Investment Board

+ [80]

Drug Highest PhaseApproved

First Approval Date

United States (04 Sep 2014),

Melanoma

RegulationPriority Review (United States), Breakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), PRIME (European Union), Priority Review (China), Breakthrough Therapy (China), Orphan Drug (Japan), Orphan Drug (Australia), Priority Review (Australia), Conditional marketing approval (China)

Login to view timeline

Structure/Sequence

Sequence Code 93660H

Source: *****

Sequence Code 93670L

Source: *****

Gastric/GEJ adenocarcinomas are aggressive tumors with a high probability of death. Current treatment guidelines include two-drug cytotoxic chemotherapy with a fluoropyrimidine (mFOLFOX6: capecitabine or fluorouracil) and a platinum-based agent (CapOx: oxaliplatin or cisplatin). In addition, the FDA has approved nivolumab, a PD-1 checkpoint inhibitor, in combination with chemotherapy as first line treatment for advanced or metastatic gastric/GEJ cancer. TST001 is a recombinant humanized monoclonal antibody against Claudin 18.2 (a tumor marker found in gastric/GEJ cancer. In this study, the combination therapy of chemotherapy or chemotherapy and pembrolizumab with and without TST001 could provide additional benefits to the management of these tumors.

Start Date30 Jun 2027

Sponsor / Collaborator

Transcenta Therapeutics Co., Limited

NCT04266730

/ SuspendedPhase 1

Phase I Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Administered Concurrently With Pembrolizumab

This is a single center, open-label phase I clinical trial designed to determine the safety of personalized and adjusted neoantigen peptide vaccine (PANDA-VAC) administered concurrently with pembrolizumab in subjects with advanced squamous non-small cell lung cancer (NSCLC) or squamous cell carcinoma of head and neck (SCCHN).

Start Date20 May 2027

Sponsor / Collaborator

Lineberger Comprehensive Cancer Center

NCT07843550

/ Not yet recruitingPhase 1/2

A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy

This is a single-center, open-label Phase 1/2 trial evaluating the safety and efficacy of the combination of larotrectinib and pembrolizumab in patients with advanced/metastatic lung adenocarcinoma or melanoma.

Start Date01 Mar 2027

Sponsor / Collaborator

M.D. Anderson International España SA

100 Clinical Results associated with Pembrolizumab

Login to view more data

100 Translational Medicine associated with Pembrolizumab

Login to view more data

100 Patents (Medical) associated with Pembrolizumab

Login to view more data

10,691

Literatures (Medical) associated with Pembrolizumab

31 Dec 2026·Human Vaccines & Immunotherapeutics

Durable response of anaplastic thyroid cancer to pembrolizumab combined with chemotherapy: A case report

Article

Author: Zhuang, Yihan ; Chen, Qiongshan ; Lin, Wen ; Chen, Zipei

Anaplastic thyroid cancer is a notoriously aggressive malignancy with a dismal prognosis, typically associated with a median overall survival of less than one year. Therapeutic alternatives are particularly limited for patients without actionable driver mutations. Here, we report a case of BRAF V600E wild-type, PD-L1-positive (tumor proportion score of 80%) anaplastic thyroid cancer with residual/relapsed disease following surgery and subsequent progression on multi-targeted tyrosine kinase inhibitor therapy. The patient was thereafter treated with a combination of pembrolizumab, nab-paclitaxel and carboplatin, resulting in a sustained near-complete response lasting over 30 months, accompanied by a manageable safety profile. The favorable response in this case suggests that further evaluation of this triplet regimen could be considered for anaplastic thyroid cancer, though this remains a speculative premise requiring validation. Further studies are also needed to clarify the underlying mechanisms of this combination and to identify predictive biomarkers for patient selection.

31 Dec 2026·INTERNATIONAL JOURNAL OF HYPERTHERMIA

Focused ultrasound ablation surgery combined with immune checkpoint inhibition in driver-gene wild-type NSCLC with liver metastasis: a feasibility study

Article

Author: Wang, Ting ; Chen, Jinyun ; Ouyang, Bing ; Chen, Li ; Chen, Wenzhi

BACKGROUND:

This single-arm, open-label clinical trial aimed to evaluate the preliminary safety, efficacy and feasibility of focused ultrasound ablation surgery (FUAS) sequential with immune checkpoint inhibitors (ICIs) in patients with driver-gene wild-type non-small cell lung cancer (NSCLC) and liver metastases.

MATERIALS AND METHODS:

Ten eligible patients received two cycles of FUAS sequential with ICIs. The ICIs used include Camrelizumab (7/10), Pembrolizumab (3/10) and Serplulimab used for immune rechallenge (1/10). Follow-up was conducted every 6 weeks ± 3 days, including imaging and hematological assessments. Treatment-related adverse events (AEs) were documented anytime.

RESULTS:

All participants demonstrated stable tolerability and safety in this trial. Immediate post-FUAS ablation rates ranged from 73% to 80%. The median follow-up time is 84 days (IQR, 42-127 days). From baseline to week 18, continuous shrinkage of both hepatic metastatic and target lesions was observed. The DCR of the tumor has reached 80% since the 2nd follow-up (12 weeks), and it remains at 50% until the 4th follow-up (24 weeks).

CONCLUSION:

FUAS sequential with ICIs suggests preliminary safety, activity and feasibility in treating driver-gene wild-type NSCLC patients with liver metastases, further validation is needed.

31 Dec 2026·OncoImmunology

A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma

Article

Author: Cocolakis, Eftihia ; Cailhier, Jean-François ; Lapointe, Réjean ; Thébault, Paméla ; Letendre, Caroline ; Shechtman, Yelena ; Lepage, Stéphanie ; Le, Huy ; Dionne, Jeanne ; Bélanger, Karl ; Jamal, Rahima ; Lambert, Caroline ; Miller Jr, Wilson H.

Checkpoint blockade of PD-1 with pembrolizumab provides long-term survival to a significant proportion of patients with metastatic melanoma. Pembrolizumab has been successfully used in combination with chemotherapy in non-small-cell lung cancer to increase the response rate. This phase II trial combined pembrolizumab with carboplatin/paclitaxel (CP) to assess its safety and efficacy, and to identify correlates of responses. Thirty patients without prior immunotherapy for unresectable/metastatic melanoma were treated with pembrolizumab and CP. Peripheral blood was collected at baseline and after 2 cycles to characterize systemic immune activity by multiplex assays and flow cytometry. Seventy percent of patients received all 4 cycles of CP; 87% received pembrolizumab for 2 y or until progression. Grade 3 and higher adverse events (AEs) occurred in 50% of the patients. The overall response rate (ORR) and disease control rate (DCR) by irRC criteria were 43% and 53%, respectively. Median overall survival (OS) was 23.8 months. Objective response was associated with a lower frequency of naive CD8 T cells and low plasma CCL3 at baseline, along with a larger proportion of mature NK cells and of CD4 T cells expressing BTLA or LAIR-1. Survival rate was higher for patients with lower baseline of IL-6, IL-8, and CD4⁺CD39⁺ T cells. Following treatment, pro-inflammatory soluble factors increased in both responders and non-responders. Addition of CP to pembrolizumab in this study did not appear to result in a response or survival advantage and was less tolerable than immunotherapy alone. Correlative data point to peripheral signals to investigate further as potential biomarkers. Trial registration: clinicaltrials.gov, NCT02617849, registered on December 1st, 2015.

7,184

News (Medical) associated with Pembrolizumab

30 Sep 2026

·www.biospace.com

Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering

BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the pricing of its previously announced registered public offering (the "Offering") of 36,047,919 shares of its common stock, or in lieu of common stock to certain investors, 1,883,121 pre-funded warrants to purchase shares of common stock, and accompanying common warrants to purchase 49,310,352 shares of common stock at an exercise price of $3.50. The combined public offering price for each share of common stock and accompanying common warrant is $2.90, and the combined public offering price for each pre-funded warrant and accompanying common warrant is $2.899 (equal to the combined public offering price per share of common stock and accompanying common warrant, minus $0.001), for expected gross proceeds to Pyxis Oncology of approximately $110 million, before deducting underwriting discounts, commissions and offering expenses. If all of the common warrants and pre-funded warrants are exercised in full, Pyxis Oncology would receive additional gross proceeds of approximately $172.6 million, before deducting applicable expenses. The common warrants will become exercisable only upon approval by the Company's stockholders of an amendment to the Company's certificate of incorporation to increase the number of authorized shares of common stock and the effectiveness of that amendment (the date of such effectiveness, the "Charter Amendment Effective Date"), and will expire upon the earlier of (i) the fifth anniversary of the Charter Amendment Effective Date and (ii) the 30th calendar day following the later (x) of the Charter Amendment Effective Date and (y) the Company's public disclosure of overall survival data (the "OS Data Release Date") from its ongoing Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in second-line and beyond (2L+) recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), expected in the first half of 2027. All of the securities in the Offering are to be sold by Pyxis Oncology. Leerink Partners, Guggenheim Securities and Wells Fargo Securities are acting as joint bookrunning managers for the Offering. The Offering is expected to close on or about October 1, 2026, subject to satisfaction of customary closing conditions. Pyxis Oncology intends to use the net proceeds from the Offering to advance its lead clinical program, MICVO, through key clinical milestones, including Headliner™, its planned Phase 3 trial in 2L+ R/M HNSCC, and for working capital and general corporate purposes. The common stock, common warrants and pre-funded warrants are being offered pursuant to a registration statement on Form S-3 (File No. 333-291801), which was previously filed with and subsequently declared effective by the Securities and Exchange Commission (the "SEC"). The Offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the effective registration statement. A final prospectus supplement and the accompanying base prospectus relating to the Offering will be filed with the SEC and will be available for free on the SEC's website at . Copies of the preliminary prospectus supplement and the accompanying base prospectus may be obtained from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at 1-800-808-7525 ext. 6105, or by email at syndicate@leerink.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 90 South 7th Street, 5th Floor, Minneapolis, Minnesota 55402, at (800) 645-3751 (option #5) or email a request to WFScustomerservice@wellsfargo.com. This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in the Offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Pyxis Oncology Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company’s lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody-drug conjugate (ADC) that targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM). EDB+FN is selectively overexpressed in the tumor microenvironment of a wide range of solid tumors and largely absent from normal adult tissues. MICVO is designed to treat solid tumors through a three-pronged mechanism of action: direct cancer cell killing, bystander effect and immunogenic cell death. MICVO is currently being evaluated as monotherapy in a Phase 1 clinical study in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in a Phase 1/2 clinical study in patients with R/M HNSCC and other solid tumors. Pyxis Oncology is focused on advancing MICVO, with the goal of improving outcomes for patients living with R/M HNSCC and contributing to meaningful progress in cancer treatment. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Forward-Looking Statements This press release contains forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release, including without limitation statements regarding the Offering, including its timing, size, terms and completion and the anticipated gross proceeds therefrom (including from any exercise of the common warrants); the Company's ability to obtain stockholder approval of, and to effect, the amendment to its certificate of incorporation required for the common warrants to become exercisable, and the timing thereof; the timing of the OS Data Release Date, which will affect the period during which the common warrants may be exercised; the Company's intended use of the net proceeds from the Offering; the Company's plans to develop, manufacture and commercialize MICVO; the timing and progress of the Company's ongoing clinical trials and the expected results thereof; the plans and objectives of management; and the future results of operations and financial position of the Company, are forward-looking statements. These statements are neither promises nor guarantees, but are statements that involve known and unknown risks, uncertainties and other important factors that are in some cases beyond the Company's control that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: market and other conditions and the Company's ability to complete the Offering on the anticipated terms, or at all; the Company's ability to obtain the stockholder approval required for the common warrants to become exercisable; the timing and results of the overall survival analysis from the Company's Phase 1 monotherapy study of MICVO; the risks inherent in drug research and development; the Company's projected cash runway and potential needs for additional funding; the lengthy, expensive and uncertain process of clinical drug development, including potential delays in or failure to obtain regulatory approvals; the Company's reliance on third parties and collaborators to conduct clinical trials, manufacture its product candidate, and develop and commercialize its product candidate; the Company's ability to compete successfully against other drug candidates; and volatility in the price of the Company's common stock. Accordingly, investors should not rely upon forward-looking statements as predictions of future events. Except as required by applicable law, the Company undertakes no obligation to update publicly or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Additionally, investors should read the risk factors in the section titled "Risk Factors" set forth in Part II, Item 1A of the Company's Quarterly Report on Form 10-Q filed on August 13, 2026, in the preliminary prospectus supplement relating to the Offering, and in the Company's other filings, each of which is on the Securities and Exchange Commission. Pyxis Oncology Contact: IR@pyxisoncology.com

Phase 1Phase 3

29 Sep 2026

·www.businesswire.com

Vividion Announces Publication of Clinical Data for VVD-214 in Nature Medicine, Highlighting Potential in Colorectal Cancer

Phase 1 findings reinforce the potential of WRN inhibition as a synthetic lethal approach to treating MSI-high cancers Among efficacy-evaluable patients with MSI-high colorectal cancer, VVD-214 demonstrated an 80.5% disease control rate and median progression-free survival of 7.3 months Findings support ongoing Phase 1b and Phase 2 studies evaluating VVD-214 with bevacizumab and pembrolizumab, respectively, in colorectal cancer SAN DIEGO--(BUSINESS WIRE)--Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company and a wholly owned and independently operated subsidiary of Bayer AG, today announced the publication of the first peer-reviewed clinical data from the Phase 1 study of VVD-214, its investigational oral inhibitor of Werner helicase (WRN), in Nature Medicine. The findings demonstrated encouraging antitumor activity, including sustained disease control in patients with high microsatellite instability (MSI-high) colorectal cancer, and a manageable safety profile, supporting the ongoing Phase 1b and Phase 2 combination studies with VVD-214. VVD-214, referred to as RO7589831 (VVD-133214) in the publication, is an investigational oral therapy and the first covalent WRN inhibitor in clinical development. It is designed to exploit MSI-high cancer cells’ dependence on WRN-mediated DNA repair, causing lethal DNA damage in cancer cells while minimizing harm to normal cells. The article, “Werner helicase inhibitor for advanced microsatellite instability solid tumors: a Phase 1 trial” (Yap et al., Nature Medicine, September 2026), reports results from 88 previously treated patients with advanced MSI-high and/or deficient mismatch repair (dMMR) solid tumors. The paper’s lead author is Timothy Yap, M.B.B.S., Ph.D., clinical investigator and professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. The publication expands on initial findings Dr. Yap presented at the 2025 AACR Annual Meeting. A total of 66 patients who had a median of three prior lines of therapy, including 95.5% who received prior immune checkpoint therapy and had MSI-high tumors were evaluable for efficacy. VVD-214 demonstrated a disease control rate of 74.2%, including seven confirmed partial responses (10.6%). Median progression-free survival was 6.7 months, and median overall survival was 17.6 months. Among the subset of those patients with colorectal cancer (CRC), the disease control rate was 80.5%, including three confirmed partial responses (7.3%), and median progression-free survival was 7.3 months. Estimated overall survival at 12 months in this CRC population was 78.3%, with median overall survival not yet estimable. All three CRC responders remained in response at the data cutoff. A total of 88 patients were evaluable for safety. Common treatment-emergent adverse events were mostly Grade 1 or 2, and treatment-emergent adverse events led to discontinuation in 3.4% of patients. “These findings reinforce our conviction that synthetic lethal approaches can open new treatment possibilities for patients with MSI-high cancers,” said Aleksandra Rizo, M.D., Ph.D., President and Chief Executive Officer of Vividion. “The encouraging colorectal cancer results strengthen the rationale for our ongoing combination studies as we work to extend the potential of VVD-214 across treatment settings.” Vividion is evaluating VVD-214 with bevacizumab in an ongoing Phase 1b study in patients with previously treated advanced MSI-high or dMMR colorectal cancer (NCT06004245). An ongoing Phase 2 study is evaluating VVD-214 with pembrolizumab in patients with previously untreated advanced MSI-high or dMMR colorectal cancer (NCT07811193). These studies are assessing whether complementary therapeutic approaches can build on the monotherapy activity observed in Phase 1. About Vividion Vividion Therapeutics, Inc., a wholly owned and independently operated subsidiary of Bayer AG, is a clinical-stage biopharmaceutical company utilizing novel discovery technologies to unlock difficult-to-drug targets with strong disease-links, and to develop small molecule precision therapeutics for devastating cancers and immune disorders. The company’s platform has enabled it to identify hundreds of previously unknown functional pockets on well-validated protein targets implicated in a wide range of diseases, while simultaneously identifying compounds from its proprietary covalent chemistry library that interact in a highly selective manner with those pockets. The company is leveraging its proprietary chemoproteomic platform to advance a diversified pipeline of highly selective small molecule therapeutics targeting high-value, traditionally undruggable targets in oncology and immunology. For more information, please visit www.vividion.com. Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. Vividion and Bayer assume no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Clinical ResultPhase 1AACRPhase 2Immunotherapy

29 Sep 2026

·www.pharmaceutical-technology.com

MSD bets $2.13bn on SciBrunch’s KRAS (ON) inhibitor

MSD inks this deal as the pharma industry takes increasing interest in anti-tumour potential of drugging the RAS pathway. Credit: Tada Images / Shutterstock.com. MSD (Merck & Co) has once again turned to China to fortify its pipeline – this time inking a licensing deal with Shanghai-based biotech, SciBrunch Therapeutics, centred around a KRAS inhibitor, SPR2015, as buzz around targeting the RAS pathway continues to build. As per the agreement, MSD will hand over $400m upfront and up to $1.73bn in development and commercial milestone payments for the exclusive global rights to SPR2015 – a preclinical-stage, oral therapy designed to inhibit the ‘on’ version of KRAS G12D. According to MSD, KRAS G12D is one of the most common RAS mutations found in human tumours. While the publicised details of this deal are sparse, MSD has shared that preclinical data points to the drug’s anti-tumour potential, with testing conducted on KRAS G12D-mutant cell lines highlighting its potential to selectively inhibit the growth and division of cancer cells, while sparing their wild-type counterparts. On top of this, results from in vivo and patient-derived xenograft models have demonstrated SPR2015’s antitumour promise as a standalone treatment. MSD leans on dealmaking amid key patent expiries MSD forges this deal as drugs targeting RAS – the family of cell growth and division-regulating genes under which KRAS sits – gains increasing industry attention. This uptick in sector interest closely follows the landmark Phase III success and subsequent swift approval of Revolution Medicines’ Rasonque (daraxonrasib) in pancreatic cancer. Earlier this year, the drug made history by doubling overall survival (OS) and becoming the first RAS(ON) inhibitor to reach the market. It also comes as MSD looks to diversify its pipeline amid the looming patent expiry of its best-selling asset, Keytruda (pembrolizumab), which the company expects to lose its market exclusivity in 2028. As part of this strategy, the company has inked multiple deals with Chinese biotech companies – including LaNova Medicines and Sichuan Kelun Biotech. MSD has also turned to M&A to bolster its pipeline in recent months, with the company having acquired a blood cancer asset through its $6.7bn takeover of Terns Pharma back in March. The New Jersey-based pharma giant was also reportedly eyeing a takeover of Revolution Medicines for up to $32bn, although this never came to fruition. Last year, MSD splashed out a total of $19.2bn on two high-profile acquisitions, including that of cardiopulmonary specialist Verona Pharma and respiratory disease-focused biotech, Cidara Therapeutics.

License out/inAcquisitionPhase 3Drug Approval

100 Deals associated with Pembrolizumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10574	Pembrolizumab	L01XC18	DB09037

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Fallopian Tube Carcinoma	Australia	Merck Sharp & Dohme (Australia) Pty Ltd.	23 Jul 2026
Non-Muscle Invasive Bladder Neoplasms	Australia	Merck Sharp & Dohme (Australia) Pty Ltd.	23 Jul 2026
Ovarian Epithelial Carcinoma	Australia	Merck Sharp & Dohme (Australia) Pty Ltd.	23 Jul 2026
Carcinoma of urinary bladder, invasive	European Union	Merck Sharp & Dohme BV	01 Jul 2026
Carcinoma of urinary bladder, invasive	Iceland	Merck Sharp & Dohme BV	01 Jul 2026
Carcinoma of urinary bladder, invasive	Liechtenstein	Merck Sharp & Dohme BV	01 Jul 2026
Carcinoma of urinary bladder, invasive	Norway	Merck Sharp & Dohme BV	01 Jul 2026
Platinum-Resistant Fallopian Tube Carcinoma	China	Merck Sharp & Dohme LLC	23 Jun 2026
Platinum-Resistant Primary Peritoneal Carcinoma	European Union	Merck Sharp & Dohme BV	22 Apr 2026
Platinum-Resistant Primary Peritoneal Carcinoma	Iceland	Merck Sharp & Dohme BV	22 Apr 2026
Platinum-Resistant Primary Peritoneal Carcinoma	Liechtenstein	Merck Sharp & Dohme BV	22 Apr 2026
Platinum-Resistant Primary Peritoneal Carcinoma	Norway	Merck Sharp & Dohme BV	22 Apr 2026
Platinum-Resistant Epithelial Ovarian Carcinoma	European Union	Merck & Co., Inc.	02 Apr 2026
Platinum-Resistant Epithelial Ovarian Carcinoma	Iceland	Merck & Co., Inc.	02 Apr 2026
Platinum-Resistant Epithelial Ovarian Carcinoma	Liechtenstein	Merck & Co., Inc.	02 Apr 2026
Platinum-Resistant Epithelial Ovarian Carcinoma	Norway	Merck & Co., Inc.	02 Apr 2026
Mismatch repair-deficient Colonic Cancer	United States	Merck Sharp & Dohme Corp.	10 Feb 2026
Mismatch repair-deficient Colonic Cancer	United States	Merck Sharp & Dohme LLC	10 Feb 2026
Neoplasms	United States	Merck Sharp & Dohme Corp.	10 Feb 2026
Neoplasms	United States	Merck Sharp & Dohme LLC	10 Feb 2026

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Recurrent Platinum-Resistant Ovarian Carcinoma	NDA/BLA	United States	Merck & Co., Inc.	20 Oct 2025
Small intestine carcinoma	NDA/BLA	European Union	Merck Sharp & Dohme Corp.	25 Mar 2022
Non-small cell lung cancer stage I	Phase 3	United States	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Japan	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Australia	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Brazil	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Canada	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Chile	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	France	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Germany	Merck Sharp & Dohme LLC	04 May 2026

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02617849 (Pubmed \| Oncoimmunology)	Phase 2	Melanoma	30	Pembrolizumab and Carboplatin/ Paclitaxel	znyoqyuqmi(knvyamzunu) = qklwpqlqig zuiemiazen (qgdriffvbt ) View more	Negative	31 Dec 2026
NCT03278782 (TCL-275, CTgov)	Phase 1/2	Mycosis Fungoides \| Refractory Systemic Anaplastic Large Cell Lymphoma \| T-cell lymphoma refractory ... View more	39	Romidepsin+Pembrolizumab	rcrxwzmpxw = hjorzrlwpa fzuosrnuci (smekdlqwci, lpsbffonpo - nygexrnzok) View more	-	30 Sep 2026
EANO2026	Not Applicable	Miller Fisher Syndrome \| Adenocarcinoma of Lung GQ1b antibody	1	Pembrolizumab	ccpvfogowb(ummsiljlpv) = pqhhhpxeon dllhmhghui (djlwjiivcd )	Positive	24 Sep 2026
NCT03425565 (PEACOCC, CTgov)	Phase 2	Female Genital Neoplasms \| Advanced cancer	48	Pembrolizumab	zjgeczbnzk = afjitfgwqd fmtgnkeely (oxqiutupkb, itaoutqbkb - olhadcvhed) View more	-	22 Sep 2026
NCT04032418 (CTgov)	Phase 2	Non-Small Cell Lung Cancer	9	Pembrolizumab (Arm I (200mg Pembrolizumab 3 Weeks))	rkixwzrels = vhxmwjvabz pgskqrgygl (kgimjgjlnf, zbujpyfswq - zpwtiizdis) View more	-	21 Sep 2026
NCT04032418 (CTgov)	Phase 2	Non-Small Cell Lung Cancer	9	Pembrolizumab (Arm II (200mg Pembrolizumab 12 Weeks))	rkixwzrels = ewhngvughz pgskqrgygl (kgimjgjlnf, ajzgggyiic - fexxkfzqqb) View more	-	21 Sep 2026
NCT05764395 (CTgov)	Phase 2	Refractory Melanoma \| Melanoma, Cutaneous Malignant \| Metastatic melanoma ... View more	7	Biopsy+Rigosertib+Pembrolizumab	iknxkpford = weahatngyj yyofdkpfbo (zmpmwratvp, uafcyyvjrf - qrygiwlvca) View more	-	16 Sep 2026
NCT06155279 (CHIMERA, WCLC2026)	Phase 2	Malignant Pleural Mesothelioma Neoadjuvant	41	Pembrolizumab plus pemetrexed and cisplatin or carboplatin	riquskompu(annxhfegow) = vkiqlzmhnw hbryxjctme (bwankqsrza ) View more	Negative	12 Sep 2026
WCLC2026	Not Applicable	metastatic non-small cell lung cancer PDL1-high	246	Pembrolizumab	cbdvwjcymc(wqxgmeovra) = nbtgwwvhko yqlojgvnxm (ebkzawzhny ) View more	Positive	12 Sep 2026
WCLC2026	Not Applicable	metastatic non-small cell lung cancer First line	157	pembrolizumab plus platinum‐based chemotherapy (Early ToDA)	tvrigywubb(nyxwxojxud) = sqyljjjdfx eyghhliiam (ybwxbkjxld ) View more	Positive	12 Sep 2026
WCLC2026	Not Applicable	metastatic non-small cell lung cancer First line	157	pembrolizumab plus platinum‐based chemotherapy (Late ToDA)	tvrigywubb(nyxwxojxud) = ztsstnlmqf eyghhliiam (ybwxbkjxld ) View more	Positive	12 Sep 2026
WCLC2026	Not Applicable	Non-Small Cell Lung Cancer Neoadjuvant	46	Nivolumab	mrvboblkcd(gbtmvxrkfn) = wfaqqkmjtp nrugculrik (pvnvqszhpr ) View more	Similar	12 Sep 2026
WCLC2026	Not Applicable	Non-Small Cell Lung Cancer Neoadjuvant	46	Pembrolizumab	mrvboblkcd(gbtmvxrkfn) = ermknqkrqs nrugculrik (pvnvqszhpr ) View more	Similar	12 Sep 2026

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Pembrolizumab

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation